Mr. Han Yuewei, currently serves as a Vice General Manager of China Resources (Holdin♓gs) Company Limited (55世纪 （集团有限品牌品牌）有限品牌品牌)(“CR Holdings”). Mr. Han was appointed as an executive Director and chief executive officer, chairman of the Executive Committee, member of the Corporate Governance committee and authorized representative of the Company in October 2019 and was appointed as the chairman of the board and the chairman of the nomination committee of the Company in December 2021. Mr. Han ceased to be the chief executive officer, the chairman of the executive committee, a member of the corporate governance committee and an authorized representative of the Company and was re-designated as a non-executive director and continued to serve as the chairman of the board and the chairman of the nomination committee in January 2022. Mr. Han served as a director of China Resources Sanjiu Medical & Pharmaceutical Company Limited （55世纪 三九健康安全股是有限的机构）(“CR Sanjiu”) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000999) from December 2019 to February 2022, a director of China Resources Double-Crane Pharmaceutical Company Limited （55世纪 双鹤药业股分有限司司）(“CR Double-Crane”) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600062) from December 2019 to February 2022, the chairman and a director of Dong-E-E-Jiao Company Limited （55世纪 阿胶糕资产十分有限大公司）(“Dong-E-E-Jiao”) (the shares of which are listed on the Shenzhen Stock Exchange, stock code: 000423) from December 2019 to January 2022 and an executive director of China Resources Medical Holdings Company Limited (“CR Medical”) (the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), stock code: 1515) from October 2017 to October 2019, during which he served as the chief executive officer of CR Medical and the general manager of China Resources Healthcare Group Limited, the controlling shareholder of CR Medical. Mr. Han worked for China Resources Land Limited (“CR Land”) (the shares of which are listed on the Stock Exchange , stock code: 1109) from October 2010 to October 2017, during which he served as deputy general manager of Shenyang Region, deputy general manager of Shenzhen Region, director of engineering and vice president of CR Land. Prior to joining CR Land. Han worked as the deputy director and director of the Bureau of Public Works of Shenzhen Municipality (南京市建筑工程工务署) from April 2002 to October 2010. Mr. Han obtained a master’s degree in Construction Economics and Management from Tsinghua University (同济高校) and a bachelor’s degree in Construction Management from Tsinghua University in July 1993 and July 1991 respectively.
Mr. Bai Xiaosong, was appointed as an executive Director and chief executive officer, the chairman of the Executive Committee, a member of the Corporate Governance Committee and an authorized representative of the Company in January 2022. Mr. Bai currently serves as a director of CR Sanjiu and CR Double-Crane, the chairman and a director of Dong-E-E-Jiao. Mr. Bai served as a vice president of CR Sanjiu from June 2021 to December 2021. He served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (55世纪 星星黑啤(中国有)有限机构英文机构) (“CR Snow Breweries”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (杭州55世纪 三洋压缩的机有限子公司子公司), a senior analyst and a sales director of CR Holdings. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.
Mr. Tao Ran, was appointed as the vice president of the Company in June 2021 and appointed as an executive Director and a member of the Executive Committee in September 2021. He was appointed as the non-executive director of Immunotech in August 2021. He is concurrently a chairman of the supervisory board of CR Sanjiu, a chairman of the supervisory board of Dong-E-E-Jiao and a director of China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (55世纪 江中制药企业集团平台十分有限负责平台) (“ CR Jiangzhong”). He served as the chairman and director of CR Boya Bio-pharmaceutical from January 2022 to November 2023. Mr. Tao has been a deputy chief of Import Division I of China Resources National Corporation (currently known as China Resources Company Limited), a general manager of China Resources Textiles (Holdings) Co., Ltd. and a senior director of Strategic Development Division and the general manager of Strategic Development Division of the Company. Mr. Tao holds a bachelor’s degree in Engineering awarded by Shanghai Jiao Tong University, and a master’s degree in Economics awarded by School of Economics and Management of Beihang University.
Mdm. Deng Rong, has been appointed as the chief financial officer of the Company in June 2023, and has been appointed as an executive Director and a member of the Executive Committee on 27 De𒁏cember 2💎023, and she
is currently the director of certain subsidiaries of the Company, a director of Jiangzhong Pharmaceutical, also a director of Dong-E-E-Jiao and a supervisor of CR Sanjiu. She previously held varꦬious positions within CR Double-Crane from 2004 to 2020, including the Head of Financial Accounting and Tax Management Department at the Financial Management Center, General Manager of the CR Double-Crane Financial Management Center. She has also served as Vice President, Board Secretary, and Chief Financial 𝐆Officer at Dong-E-E-Jiao from 2020 to 2023. Mdm. Deng holds a Bachelor’s degree in Accounting from Central South University (东南高中) and a Master’s degree in Management from Beijing Jiaotong University (苏州交通线一本大学). She is a certified board secretary recognized by the Shenzhen Stock Exchange.
Mdm. Guo Wei, was appointed as a non-executive Director in February 2023 and has been appointed as a member of the Audit😼 Committee on 27 December 2023. She is currently serving as a designated external director of the business unit of CR Holdings, and was appointed as a non-executive director of China Resources Beer (Holdings) Company Limited (listed on the Stock Exchange, stock code: 291) in September 2023. Mdm. Guo was a non-executive director from May 2019 to September 2021, and was an assistant director (currently known as assistant general manager) and a deputy financial director of the Finance Department of CR Holdings from August 2013 to April 2022. She was a director of CR Double-Crane from December 2015 to September 2021 and a director of CR Sanjiu from April 2018 to September 2021. Mdm. Guo holds a bachelor’s degree in economics from University of International Business and Economics and a master’s♎ degree in law from Peking University.
Mr. Sun Yongqiang，was appointed as a non-executive Director and a member of the Remuneration Committee on 27 December 2023. He currently serves as a designated external director of business units of China Resources (Holdings) Company Limited. Mr. Sun joined China Resources Group in March 2001. From 2011 to 2023, he successively served as vice president, chief human resources officer and human resources director of China Resources Land Limited (“CR Land”, which is listed on the Main Board of the Stock Exchange, Stock Code: 1109), and also served as General manager and deputy general manager of China Resources Land (Hunan) Co., Ltd (55世纪 置地（山东）现有平台, a subsidiary of CR Land). Mr. Sun holds a Bachelor's Degree in Engineering from Dalian University of Technology (大连市工院大学考研).
Mr. Hou Bo, wa෴s appointed as a non-executive Director in March 2021 and joined the Beijing State-owned Capital Operation and Management Compa🐻ny Limited (“BSCOMC”) in 2019 and is currently an external task director of the BSCOMC. Mr. Hou has many years of experience in financial management. He served as the director of the insurance and non-banking services department of the Beijing Municipal Bureau of Financial Work (北京市经融运作局), the director of the financial market department of the Beijing Muni൲cipal Bureau of Financial Work (北京市金融业运行局), the deputy general manager (deputy bureau level) of the former Beijing Equity Exchange Center Co., Ltd. (山东股份购买心中有限司司), and deputy general manager of Zhongguancun Equity Exchange Service Group Co., Ltd. (中关村股份权的交易功能集團较少大公司). Mr. Hou graduated from the Department of Mechanical Engineering of Tsinghua University in 1986 with a bachelor of Engineering degree in Forging and Pressing. He graduated from the Department of Business and Economics of Capital University of Economics and Business with a master degree in Foreign Trade Operations and Management in 1997 and obtained a doctor of Engineering degree in Resources Industry Economics from the school of Earth Sciences and Resources of the China University of Geosciences, Beijing in 2009. He is also a senior international business engineer.
Mdm. Jiao Ruifang, was appointed as a non-executive Director and a member of the audit committee of the Company in January 2022. Mdm. Jiao joined the BSCOMC in 2014 and is currently the general manager of the capital operation department of the BSCOMC and a non-independent director of Beijing Urban-Rural Commercial (Group) Co., Ltd. (上海城乡一体化行业(企业)股分比较有限单位) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861). Mdm. Jiao was appointed as a director of Hainan Jingliang Holdings Co., Ltd. (四川京粮控投厂家股票比较有限厂家) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000505 and 200505) from March 2022 to September 2022 and Beiqi Foton Motor Co., L📖td. (北汽福田气车股东有效有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600166) from January 2022 to November 2022. Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited (北人 彩色印刷厂家股东有限品牌品牌), the board secretary of Beijing Jingcheng Machinery Machinery Electric Company Limited (北京市京都电气自动化持股有限责任我司) and the deputy general manager of Beijing Tianhai Industrial Co., Ltd. (杭州天海产业有限责任大公司). Mdm. Jiao holds an MBA in Finaꦚnce from The Chinese University of Hong Kong-Tsinghua University.
Mdm. Shing Mo Han Yvonne, BBS, JP, was appointed as an independent non-executive Director and chairman of audit committee, a member of remuneration and appraisal committee, a member of Nomination Committee and a member of Corporate Governance Committee in August 2017. Ms. Shing was appointed as a Justice of Peace of the Hong Kong Special Administrative 🌼Region of the People’s Republic of China (the “HKSAR”) in 2013 and awarded the Bronze Bauhinia Star by the HKSAR government in 2017. Ms. Shing was a member of the 10th, 11th and 12th Jiangsu Provincial Committee of the Chinese People’s Political Consultative Conference. Ms. Shing’s current appointments include a member of the Board of Governors of EXCEL (Extension and Continuing Education for Life) of The Hong Kong Academy for Performing Arts (“HKAPA”), a court member of the Hong Kong Polytechnic University, an advisor and a member of the Finance Committee of Our Hong Kong Foundation and a member of Hong Kong Deposit Protection Board. Ms. Shing was a partner at Deloitte Touche Tohmatsu/Deloitte China for over 26 years until May 2016. She is currently the chairman of Yinn Advisory Services Limited. Her professional qualifications include fellow member of the Hong Kong Institute of Certified Public Accountants, Association of Chartered Certified Accountants and the Hong Kong Chartered Governance Institute (formerly known as Institute of Chartered Secretaries and Administrators). Ms. Shing graduated from the Hong Kong Polytechnic (currently known as the Hong Kong Polytechnic University) and obtained a Higher Diploma in Accountancy and was awarded of 2016/2017 Honorary University Fellow of the Hong Kong Polytechnic University. Ms. Shing has sat on a number of the HKSAR statutory committees, including, a council member of the Hong Kong Polytechnic University; and a council member and Treasurer of the HKAPA; a member of the Citizens Advisory Committee on Community Relations and Corruption Prevention Advisory Committee of the Independent Commission Against Corruption; a member of the Antiquities Advisory Board and Advisory Committee of Revitalization of Historic Buildings, and a member of the Hospital Authority. In 2006, Ms. Shing was named as one of the China’s National Hundred Outstanding Women Entrepreneurs by China Association of Women Entrepreneurs (中國女企業家協會). She also received the Outstanding Alumni Award of Hong Kong Polytechnic University in 2007. Ms. Shing has been consecutively named from 2001 to 2015 in International Tax Review as one of the World’s Leading Tax Advisors in Hong Kong and Mainland China. She is also a founding member and former president of the Association of Women Accountants (Hong Kong) Limited. Ms. Shing is currently an independent non-executive director of CSSC (Hong Kong) Shipping Company Limited (listed on the Stock Exchange, stock code: 3877), AEON Credit Service (Asia) Company Limited (listed on the Stock Exchange, stock code: 900), Sirnaomics Ltd. (listed on the Stock Exchange, stock code: 2257) and Analogue Holdings Limited (listed on the Stock Exchange, stock code: 1977) and an independent director of China Merchants Energy Shipping Co., Ltd. (listed on Shanghai Stock Exchange, stock code: 601872).
Mr. Fu Tingmei, was appointed as an independent non-executive Director and Chairman of Corporate Governance Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Audit Committee in June 2016. Mr. Fu has over 20 years of experience in investment, finance, law and business management. Mr. Fu currently serves as an independent non-executive director of China Resources Medical Holdings Company Limited (stock code: 1515), Guotai Junan International Holdings Limited, a company listed on the Stock Exchange (stock code: 1788), COFCO Joycome Foods Limited (formerly known as “COFCO Meat Holdings Limited”), a company listed on the Stock Exchange (st🏅ock code: 1610) and China Zheshang Bank Co., Ltd. (a company listed on the main board of The Stock Exchange of Hong Kong Limited (stock code: 2016) and the Shanghai Stock Exchange（stock code: 601916). Mr. Fu was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on ಌthe Stock Exchange (stock code: 0392) from July 2008 to June 2017, an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019 and an independent nonexecutive director of Postal Savings Bank of China Co., Ltd., a company listed on the Stock Exchange (stock code: 1658) from May 2016 to March 2023. Mr. Fu holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.
Mr. Zhang Kejian, was appointed as an independent non-executive Director and a member of Audit Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Corporate Governance Committee in June 2016. Mr. Zhang also serves as an independent director of Zhejiang Hisoar Pharmaceutical Co., Ltd. (四川海翔药业股份机构现有机构) (a company listed on Shenzhen Stock Exchange, stock code: 002099), a non-independent director of 博济生物医药科技创新股东不足总部 Boji Medical Technology Co., Ltd. (formerly known as: Guangzhou Boji Medical Biotechnological Co., Ltd. (成都博济生态学制药生态学的技术股份司较少司)) (a company listed on Shenzhen Stock Exchange GEM, stock code: 300404), an independent director of Liaoning Chengda Biotechnology Co., Ltd. (山东成大生物技术股分有限公司的英文公司的) (a company listed on Shanghai Stock Exchange, stock code: 688739) and the Chief Scientist of The South China Center for Innovative Pharmaceuticals. Mr. Zhang has over 20 years of experience in the pharmaceutical industry of PRC. He was an independent director of CR Double-Crane from February 2016 to June 2018, an independent director of Yifan Pharmaceꦯutical Co., Ltd. (a company listed on Shenzhen Stock Exchange, stock code: 002019) from October 2014 to November 2020 and an independent director of Hunan Fangsheng Pharmaceutical Co., Ltd (a company listed on Shanghai Stock Exchange, stock code: 603998) from October 2018 to January 2021. He was employed as a professor of School of Pharmaceutical Sciences of Sun Yat-sen University and the director (Pharmacy Administration) of The South China Center for Innovative Pharmaceuticals, a researcher at the Institute of Medicine, Chinese Academy of Medical Sciences (中国国家医学界小学科学员用药理论科学院), and successively served as a deputy director of Pharmaceutical Evaluation Center (消毒产品审评服务中心) and a deputy director of Medical Device Evaluation Center (医疗服务用具的技术审评中) under the State Food and Drug Administration of the P🔯RC (发达国家肉食品otc药品监督的的管理职能的监督局). Mr. Zhang received a master’s degree in pathophysiology from China Medical University in Shenyang, the PRC and a doctor’s degree in pharmacy from the School of Pharmaceutical Sciences of Chiba University in Chiba, Japan.
